Conditions: Alzheimer's Disease
Keywords: rosiglitazone cognition cerebral glucose metabolism positron emission tomography (PET) Alzheimer's Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 80
Healthy volunteers: no

Brief summary:
This is a placebo-controlled study evaluating the effects of rosiglitazone on functional brain activity and cognition in patients with mild to moderate Alzheimer's Disease (AD).

Detailed description:

Arms:
arm 1: 4 mg once a day for 1 month increasing to 8 mg once a day (Extended Released Tablets) arm 2: Placebo dummy to match

Interventions: intervention 1: Rosiglitazone intervention 2: Placebo
Intervention descriptions: intervention 1: Extended Release Tablets intervention 2: Placebo dummy to match

Protocol document: